SAKAR Sakar Healthcare Q3 FY26 results (Oct–Dec 2025) and concall
Sakar Healthcare reported a strong Q3 FY26, with revenue growing 62% YoY to INR 7,034 lakhs and PAT surging 126% YoY to INR 1,025 lakhs, primarily driven by its oncology vertical. The company's EU GMP-approved oncology facility is now a manufacturing source for the EU, with 11 marketing authorizations secured and 10 molecules in various stages of technical transfer. Management expects this momentum to continue, projecting 60-70% YoY growth for oncology in FY27, while maintaining a controlled capex and stable tax rate due to MAT credit.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 62.8%, net profit up 100.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 43 | 50 | 53 | 58 | 70 +63% |
| EBITDA | 12 | 16 | 13 | 11 | 19 +58% |
| Net profit | 5 | 6 | 5 | 5 | 10 +100% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
